Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

OBJECTIVE: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high‐risk cytogenetic abnormalities in lenalidomide‐pretreated patients with multiple myeloma at first relapse. METHODS: OPTIMISMM was...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Schjesvold, Fredrik, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, Rodriguez‐Otero, Paula, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Beksac, Meral, Oriol, Albert, Lindsay, Jindriska, Liberati, Anna Marina, Galli, Monica, Robak, Pawel, Larocca, Alessandra, Yagci, Munci, Vural, Filiz, Kanate, Abraham S., Jiang, Ruiyun, Grote, Lara, Peluso, Teresa, Dimopoulos, Meletios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293199/
https://www.ncbi.nlm.nih.gov/pubmed/34496096
http://dx.doi.org/10.1111/ejh.13706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293199/
https://www.ncbi.nlm.nih.gov/pubmed/34496096
http://dx.doi.org/10.1111/ejh.13706

Ejemplares similares